We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+4.48%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$329M
AUM Growth
-$29.9M
Cap. Flow
-$29.1M
Cap. Flow %
-8.87%
Top 10 Hldgs %
51.54%
Holding
77
New
13
Increased
17
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.2M
2
APLS
Apellis Pharmaceuticals
APLS
+$8.46M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.07M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.94M
5
GILD icon
Gilead Sciences
GILD
+$6.94M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$40.5M
2
ALKS icon
Alkermes
ALKS
+$16.7M
3
EXEL icon
Exelixis
EXEL
+$10.5M
4
QURE icon
uniQure
QURE
+$8.77M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ERAS icon
26
Erasca
ERAS
$6.82B
$3.92M 1.19%
1,426,000
– –
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$2.59B
$3.69M 1.12%
80,052
-184,000
-70% -$8.53M
AKRO
28
DELISTED
Akero Therapeutics
AKRO
$3.66M 1.11%
+78,489
New +$3.6M
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$5.12B
$3.62M 1.1%
151,000
-65,000
-30% -$1.44M
HALO icon
30
Halozyme
HALO
$12.1B
$3.44M 1.05%
95,500
+50,000
+110% +$1.71M
DYN icon
31
Dyne Therapeutics
DYN
$4.87B
$3.38M 1.03%
300,751
-133,000
-31% -$1.57M
BIIB icon
32
Biogen
BIIB
$32.7B
$3.13M 0.95%
11,000
-10,400
-49% -$3.1M
RCKT icon
33
Rocket Pharmaceuticals
RCKT
$397M
$3.09M 0.94%
156,000
+93,000
+148% +$1.88M
LEGN icon
34
Legend Biotech
LEGN
$3.99B
$2.62M 0.8%
38,000
– –
ZLAB icon
35
Zai Lab
ZLAB
$3.01B
$2.19M 0.67%
78,958
– –
SRPT icon
36
Sarepta Therapeutics
SRPT
$2.28B
$2.15M 0.66%
+18,800
New +$2.42M
JAZZ icon
37
Jazz Pharmaceuticals
JAZZ
$16.3B
$2.13M 0.65%
17,200
– –
IONS icon
38
Ionis Pharmaceuticals
IONS
$10.4B
$1.76M 0.54%
43,000
– –
MIRM icon
39
Mirum Pharmaceuticals
MIRM
$6.08B
$1.74M 0.53%
67,500
– –
CLDX icon
40
Celldex Therapeutics
CLDX
$3.18B
$1.63M 0.5%
+48,099
New +$1.62M
ONC
41
BeOne Medicines Ltd
ONC
$42.1B
$1.55M 0.47%
8,700
-14,000
-62% -$3.22M
NVCR icon
42
NovoCure
NVCR
$2.09B
$1.33M 0.4%
32,000
– –
GH icon
43
Guardant Health
GH
$22.6B
$1.31M 0.4%
36,500
-38,000
-51% -$1.09M
CYTK icon
44
Cytokinetics
CYTK
$10.8B
$1.21M 0.37%
+37,000
New +$1.37M
XENE icon
45
Xenon Pharmaceuticals
XENE
$6B
$982K 0.3%
25,500
– –
NTLA icon
46
Intellia Therapeutics
NTLA
$1.84B
$978K 0.3%
24,000
– –
MRNS
47
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$977K 0.3%
+90,000
New +$771K
SAGE
48
DELISTED
Sage Therapeutics
SAGE
$939K 0.29%
+20,000
New +$995K
NBP
49
NovaBridge Biosciences American Depositary Shares
NBP
$219M
$925K 0.28%
310,499
– –
INSM icon
50
Insmed
INSM
$26.5B
$845K 0.26%
40,100
– –
1
2
3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2023 Portfolio in Review

As of Q2 2023, International Biotechnology Trust held 77 positions worth $329M, down 8.3% from $358M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust withdrew a net $29.1M in Q2 2023, closing 16 positions and reducing 12 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $40.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $6.89M.

  • International Biotechnology Trust's largest Q2 2023 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 67,000 shares worth $6.89M.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q2 2023, an estimated $12.2M increase.
  • International Biotechnology Trust's biggest Q2 2023 reduction was uniQure, cutting an estimated $8.77M.
  • International Biotechnology Trust fully exited Seagen Inc. Common Stock in Q2 2023, selling an estimated $40.5M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $329M portfolio in Q2 2023.
  • International Biotechnology Trust opened 13 new positions and closed 16 in Q2 2023.
  • International Biotechnology Trust's portfolio value fell 8.3% quarter-over-quarter to $329M.

Based on International Biotechnology Trust's 13F filing for Q2 2023, filed 8 Aug 2023.